Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary ...
The ranibizumab biosimilar Ongavia exhibited significantly less improvement in visual acuity and retinal thickness compared ...
An add-on agent designed to boost drugs that treat age-related macular degeneration failed to show any benefit in two phase 3 ...
Regeneron’s Eylea injection has been approved in the US for diabetic retinopathy, to treat all stages of the disease and reduce the risk of blindness. Developed in collaboration with Bayer ...
The intravitreal injection is currently undergoing two registrational ... blockbuster eye care medication Eylea with a ...
The KALAHARI study compared intravitreal injections of THR-149 to Regeneron and Bayer’s anti-VEGF antibody Eylea (aflibercept), a widely-used therapy for DME, in 112 patients for whom the ...
The Eylea franchise was in need of a win after an appellate court last week denied the pharma’s bid to block Amgen’s ...
Regeneron Pharmaceuticals announced positive three-year results from an extension study of EYLEA HD (aflibercept) Injection 8 mg for treating wet age-related macular degeneration (wAMD).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback